Please login to the form below

Not currently logged in
Email:
Password:

LCZ696

This page shows the latest LCZ696 news and features for those working in and with pharma, biotech and healthcare.

Novartis' Entresto launched in UK

Novartis' Entresto launched in UK

The results of the PARADIGM-HF study showed that patients treated with LCZ696 were 20% less likely to die from a cardiovascular cause or hospitalisation and were also 16% less likely

Latest news

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics